Moreover, anti-Sema4D and anti-VEGF antibodies have synergistic effects in inhibiting retinal neovascularization and vascular leakage, indicating the promising potential of Sema4D as a therapeutic target for retinopathy. This evidence concerns the gene SEMA4D and retinal disorder.